Goldstein, R;
Sosabowski, J;
Livanos, M;
Leyton, J;
Vigor, K;
Bhavsar, G;
Nagy-Davidescu, G;
... Chester, K; + view all
(2015)
Development of the designed ankyrin repeat protein (DARPin) G3 for HER2 molecular imaging.
Eur J Nucl Med Mol Imaging
, 42
(2)
288 - 301.
10.1007/s00259-014-2940-2.
Preview |
PDF
art_10.1007_s00259-014-2940-2.pdf Download (1MB) |
Abstract
Human epidermal growth factor receptor-2 (HER2) overexpression is a predictor of response to anti-HER2 therapy in breast and gastric cancer. Currently, HER2 status is assessed by tumour biopsy, but this may not be representative of the larger tumour mass or other metastatic sites, risking misclassification and selection of suboptimal therapy. The designed ankyrin repeat protein (DARPin) G3 binds HER2 with high affinity at an epitope that does not overlap with trastuzumab and is biologically inert. We hypothesized that radiolabelled DARPin G3 would be capable of selectively imaging HER2-positive tumours, and aimed to identify a suitable format for clinical application.
Archive Staff Only
View Item |